Xceleron, a provider of ultra-sensitive analytical technology to novel clinical designs, has partnered with Crystal Pharmatech, a China-based CRO, to offer drug developers early bioavailability data to optimize solid-state forms and formulations. The partnership will combine accelerator mass spectrometry (AMS) technology and expertise aimed at cost-effectively removing pharmacokinetic uncertainty by providing better early clinical and solid-state information.   “At Xceleron, we believe that tech...